Company News 03 Nov 2025 First Remplir™ Surgical Case Completed in Hong Kong Orthocell has announced the successful completion of the first Remplir™ surgical case in Hong Kong and the official launch of… Orthocell
Company News 30 Oct 2025 Professor Minghao Zheng elected Fellow of the Australian Academy of Health and Medical Sciences Professor Minghao Zheng, Orthocell’s Co-Founder and Chief Scientific Officer, has been elected as a Fellow of the Australian Academy of… Orthocell
Company News 29 Oct 2025 Orthocell Appoints Exclusive Remplir™ Distributor for Hong Kong Orthocell has appointed medical device distributor MontsMed as its exclusive in-country distributor for Remplir in the key Asian market of… Orthocell
Company News 20 Oct 2025 Orthocell secures global distribution rights to innovative bone regeneration technology Orthocell has signed Memorandum of Understanding to increase its equity stake in Marine Biomedical - from 1.7% to 12.0% for… Orthocell
Company News 17 Oct 2025 $30.0 Million Placement to Accelerate Global Commercialisation and Advance Product Portfolio Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement. Orthocell
Company News 10 Oct 2025 Quarterly Report – period ended 30 September 2025 Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth… Orthocell
Company News 02 Oct 2025 Orthocell Announces Record Revenue of $3m for September Quarter Orthocell has announced record quarterly revenue of $3.0 million for the September quarter – our sixth consecutive quarter of record… Orthocell
Company News 30 Sep 2025 Orthocell Appoints First Distributor for Remplir™ in US$75m Canadian Market Orthocell has appointed its first Canadian distributor for Remplir™, signalling the commencement of the Company’s commercial roll out in the… Orthocell
Media 26 Sep 2025 STOCKHEAD | Orthocell flags rapid ‘hockey stick’ revenue growth in the US$1.6 billion US nerve repair market Orthocell was featured in a Stockhead article by leading biotech journalist Tim Boreham titled “Orthocell flags rapid ‘hockey stick’ revenue… Orthocell
Company News 16 Sep 2025 Global opportunity emerges as Remplir™ is used in nerve-sparing prostate cancer surgery Orthocell has identified a promising new application for its flagship Remplir™ nerve repair device - for use in nerve-sparing Robotic-Assisted… Orthocell
